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Aim: For previously untreated patients (PUPs) with severe haemophilia A in Finland 
for the past 2 decades, the standard practice has been to start early primary prophy-
laxis. We evaluated the long- term clinical outcomes and costs of treatment with high- 
dose prophylaxis in PUPs from birth to adolescence, including immune tolerance 
induction (ITI).
Methods: From the medical records of all PUPs born between June 1994 and May 
2013 in Finland, we retrospectively extracted data on clinical outcomes and health-
care use. Using linear mixed models, we analysed longitudinal clinical outcome data. 
To analyse skewed cost data, including zero costs, we applied hurdle regression.
Results: All 62 patients received early regular prophylaxis; totally, they have had 
treatment for nearly 700 patient- years. The median age of starting home treatment 
was 1.1 years. The mean (SD) annual treatment costs (€ per kg) were 4391€ (3852). 
For ages 1- 3, ITI comprised over half of the costs; in other groups, prophylactic FVIII 
treatment dominated. With these high costs, however, clinical outcomes were desir-
able; median (IQR) ABR was low at 0.19 (0.07- 0.46) and so was AJBR at 0.06 (0- 0.24). 
Thirteen (21%) patients developed a clinically significant inhibitor, 10 (16%) with a 
high titre. All ITIs were successful. The mean costs for ITI were 383 448€ (259 085). 
The expected ITI payback period was 1.81 (95% CI 0.62- 12.12) years.
Conclusions: Early high- dose prophylaxis leads to excellent long- term clinical out-
comes, and early childhood ITI therapy seems to turn cost- neutral generally already 
in 2 years.
K E Y W O R D S
ABJR, ABR, bleed, costs, haemophilia A, health economics, outcome, prophylaxis, PUP
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1  | INTRODUC TION
Severe haemophilia A (FVIII: C < 0.01 IU/mL) is a congenital X- linked 
bleeding disorder resulting in spontaneous and trauma- induced 
bleeds, especially in joints. Prophylactic replacement therapy with 
clotting factor VIII (FVIII) concentrates has augmented the preven-
tion of the development of haemophilic arthropathy 4591; 4602. It 
offers patients a near- normal life with a life expectancy similar to 
that of males in the general population 461.3 Prophylactic FVIII 
treatment also associates with a decreased inhibitor development 
risk 413.4 Hence, early regular prophylaxis is the standard of care 
in children with severe haemophilia. Haemophilia treatment costs 
are high, with high- dose prophylaxis accounting for 95%- 99.6% of 
the total 5005; 455.6 The predicted annual total treatment costs 
for an average- weight (74 kg) adult noninhibitor patient exceed 
US$ 298 000. Paediatric cost studies with real- world data are few; 
an estimate of the average total annual costs of treating patients 
is US$ 21 600 for young children and US$ 124 000 for teenagers 
4697; 4648; 472.9 Most treatment cost reports are per patient and 
usually not per body weight, which challenges the cost comparisons. 
This is typical among different paediatric studies where patient body 
weight varies significantly, and yet dosing is based on weight.
In Finland, the treatment of all children with severe haemophilia 
either in comprehensive care or haemophilia treatment centres in 
university hospitals follows a uniformly agreed protocol. Here, it 
has been a standard practice for nearly 2 decades to start primary 
prophylaxis with a recombinant FVIII (rFVIII) for all patients below 
age one, mainly via a central venous access device (CVAD) without 
increasing the risk of inhibitor development 46510; 452.11 With a 
long follow- up, this nationwide study evaluated the long- term real- 
world outcomes and yearly patient weight- based total costs in previ-
ously untreated patients (PUPs) with severe haemophilia A with and 
without inhibitors. We also included the costs of immune tolerance 
induction (ITI). We hope the study will pave the way to uniform doc-
umentation of treatment costs of paediatric haemophilia.
2  | MATERIAL S AND METHODS
2.1 | Design and setting
This 19- year retrospective, nationwide, real- world, multicentre study 
evaluated the clinical outcomes and direct medical costs of the treat-
ment of PUPs with severe haemophilia A (FVIII coagulation activity 
<0.01 IU/mL) in Finland. We enrolled all PUPs (n = 62) born between 
June 1994 and May 2013 who had at least 75 exposure days (EDs) 
of concentrate use or who developed inhibitors until the end of the 
follow- up in September 2013. The patient cohort was the same as in 
our previous PUP study on inhibitor development in Finland 452.11 
The study involved 5 Finnish paediatric Haematology- Oncology ter-
tiary centres (Kuopio, Oulu, Turku, Tampere and Helsinki University 
Hospitals), which serve also as treatment centres of haemophilia for 
children and adolescents.
The Research Ethics committee of Northern Savo, Finland, 
provided a favourable opinion for this study (26//2010). We ob-
tained permissions to use the register data from each organization 
concerned.
2.2 | Data extraction
The principal investigator (KV) collected detailed medical history 
data from all these patients’ medical records. Patient and treatment 
characteristics data included date of birth and diagnosis, ethnicity, 
first exposure to FVIII (age and indication), prophylaxis with coagu-
lation factor concentrates, and treatment of bleeding episodes and 
surgical procedures with an FVIII concentrate or with bypassing 
agents (recombinant activated factor VII [rFVIIa] and plasma- derived 
activated prothrombin complex concentrate [aPCC]), inhibitor de-
velopment and ITI therapy. Patient- specific data included clinical 
outcomes including ITI success, coagulation factor concentrate con-
sumption and the utilization of healthcare services; for this last item, 
we used the top- down costing approach, where extracted individual 
services were valued by the national tariffs 466.12
2.3 | Prophylaxis
Detailed individual data on prophylaxis included age, type of venous 
access, number of exposure days and previous joint bleeds at the 
onset of prophylaxis. It also included the annual prophylactic regi-
men for every patient including body weight, dosage and frequency 
of prophylactic FVIII administrations. “Regular prophylaxis” was de-
fined as long- term uninterrupted administration of an FVIII concen-
trate at least once a week to prevent bleeds. “Primary prophylaxis” 
meant regular prophylaxis started before age 2 and before the onset 
of any joint bleed. “Secondary prophylaxis” covers all other long- 
term prophylactic regular treatments failing to fulfil the criteria of 
primary prophylaxis.
2.4 | Clinical outcomes and bleeding episodes
We observed the number of annual bleeds including joint bleeds and 
the number of patients with a target joint or an arthropathy. We cal-
culated the annualized bleeding rate (ABR) and the annualized joint 
bleeding rate (AJBR) as the number of (joint) bleeding episodes di-
vided by the length of follow- up time in years. We recorded all major 
and minor bleeds requiring hospitalization. We based our definition 
of a major bleed in surgical and nonsurgical settings on ISTH recom-
mendations 45313; 418.14 A joint bleed meant an episode character-
ized by an unusual sensation or “aura” in the joint in combination 
with any of the following signs: (i) increasing swelling or warmth of 
the skin over the joint, (ii) increasing pain, and (iii) progressive loss 
of range or difficulty in using the limb as compared to the baseline 
44715; 448.16 In infants and young children, a joint bleed meant re-
luctance to use the limb accompanied with either pain, or swelling or 
warmth of the skin over the joint.
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A target joint was defined as 3 or more spontaneous bleeds in 
a single joint within 6 consecutive months 44715; 448.16 A chronic 
haemophilic arthropathy meant a target joint with clinical or radio-
logical evidence of significant synovitis 448.16
2.5 | Inhibitor development and immune 
tolerance induction
Clinically significant inhibitor development was defined as at least 
2 positive antibody titres combined with a decreased in vivo FVIII 
recovery 251.17 High- titre inhibitors occurred when the peak in-
hibitor titre was at least 5 Bethesda Units (BU)/mL. We classified 
as “low responders” (LRs) patients with inhibitor titres persistently 
≤5 BU/mL despite repeated challenges with FVIII; “high responders” 
(HRs) referred to patients with inhibitor titres >5 BU/mL at any time 
447.15 Low responders received 50- 150 IU FVIII kg−1 daily, or thrice 
a week; high responders received 100 IU FVIII kg−1 every 12 hours, 
or 100- 200 IU FVIII kg−1 daily. We based our definition of ITI success 
in terms of successful tolerance and partial response on the criteria 
of the International ITI (I- ITI) study and U.S. guidelines for immune 
tolerance induction (Table 1) 45018; 451.19
2.6 | Healthcare resource use and costs
To estimate the long- term costs of treatment, we recorded the use of 
all clotting factor concentrates and healthcare services. The former 
included FVIII, rFVIIa and pd- aPCC use for prophylaxis, bleeds and 
for surgical procedures, and FVIII use for ITI. The latter comprised 
the number of hospitalizations for bleeding episodes or surgical pro-
cedures and the length of stay for each hospitalization, including 
the number of days in the ICU. We also recorded the numbers of 
outpatient visits, CVAD insertions and removals, and CVAD- related 
infections. The unit costs of the services utilized (Table 2) were ob-
tained from the national healthcare unit cost list 473,20 and all costs 
were assessed at real values (€) in 2014. The estimated costs are 
convertible to US$ using the European Central Bank annual bilateral 
exchange rates in 2014 available at sdw.ecb.europa.eu. We report all 
costs by weight adjustment, that is per kg of body weight to describe 
and compare costs between patients of different ages and weights.
2.7 | Validation
To validate the FVIII consumption data extracted from the medical 
records, we acquired a patient- specific validation sample from the 
Finnish Prescription Register maintained by the Social Insurance 
Institution (SII). This database of nationwide electronic pharmacy 
reimbursement claims became available in 1994, and it includes 
records of all medication dispensations reimbursed to community- 
dwelling residents of Finland. The register keeps no record of 
nonreimbursed medications or medications dispensed during a 
hospital stay 468.21 Our validation data sample included all study 
patients, except children living in the area of the hospital district 
of Helsinki and Uusimaa. Prior to SII data collection, all patients, 
TABLE  1 Patient and treatment characteristics
PUPs with severe haemophilia A 62
Caucasian (%) 60 (97)
Median age at diagnosis, months (range) 0.7 (0- 14.8)
Median age at first exposure to FVIII, months 
(range)
9.0 (0- 16.2)
Median age at the end of follow- up, years (range) 12.7 (1.2- 19.3)
Cumulative follow- up time, years 698
Prophylactic regimen
Patients with regular prophylaxisa (%) 62 (100)
Median age at the onset of regular prophylaxis, 
months (range)
11.8 (0.8- 51.2)
Type of a venous access at the onset of prophylaxis
Peripheral veins (%) 5 (8)
CVAD (%) 57 (92)
Median age at start of home treatment, years 
(range)
1.1 (0.2- 4.3)
Patients with primary prophylaxisb (%) 51 (82)
Patients with secondary prophylaxisc (%) 11 (18)
Type of initial FVIII concentrate used
pd- FVIII products 23 (37)
rFVIII products 39 (63)
Median dose of prophylactic FVIII, IU/kg (IQR) 26 (22- 32)
Median frequency of prophylactic infusions per 
week (IQR)
3 (3- 3.5)
Median yearly dose of FVIII, IU/kg (IQR) 4136 
(3250- 5113)
Inhibitor development
Patients who developed inhibitors (%) 13 (21)
High- titred inhibitors (%) 10 (16)
Median peak titre, BU/mL (range) 14 (1.7- 42)
Median age at ID, months (range) 11.7 (7.2- 27.7)
Median ED at ID (range) 19 (10- 61)
ITI success
Patients who started ITI 12
Patients who completed ITI 11
Patients with successful tolerancee (%) 4 (36)
Patients with partial responsef (%) 7 (64)
PUPs, previously untreated patients; FVIII, coagulation factor VIII; 
CVAD, central venous access device; IQR, interquartile range; BU, 
Bethesda unit; ID, inhibitor development; ED, exposure days; ITI, im-
mune tolerance induction.
aRegular prophylaxis, regular and long- term administration of FVIII con-
centrate at least once a week to prevent bleeds.
bPrimary prophylaxis, regular prophylaxis started before the age of 2 y 
and before the onset of the first joint bleed.
cSecondary prophylaxis, regular prophylaxis started later than the age of 
2 y or after the first joint bleed.
dHigh- titre inhibitor was defined as a peak inhibitor titre ≥5 BU/mL.
eSuccessful tolerance, a persistently negative inhibitor titre (<0.6 BU/
mL), FVIII recovery ≥66% of expected and FVIII half- life ≥6 h.
fPartial response, after 33 mo of ITI, a negative inhibitor titre, but per-
sistently abnormal FVIII recovery or half- life; the patient responds clinically 
to FVIII replacement without an anamnestic increase in inhibitor titre.
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their parents, or both, provided written informed consent. The 
validation was conducted by comparing median annual prophylac-
tic FVIII consumption estimate obtained from the medical records 
with the total amount of FVIII dispensed obtained from the SII 
registry.
2.8 | Statistical analysis
Descriptive statistics as mean and standard deviation (SD) or me-
dian and inter- quartile range (IQR) are presented; categorical vari-
ables are reported as frequencies and proportions. We analysed 
longitudinal outcome data using a linear mixed model for repeated 
measures. Hurdle modelling approach was applied to right- skewed 
cost data including excess zero values. Furthermore, nonparametric 
bootstrapping was applied to define 95% confidence intervals for 
mean cost estimates.
To demonstrate the potential economic value of ITI, an expected 
payback period estimate in years was provided to indicate the time 
period of cost savings (after the completing of ITI) needed to equal 
the overall cost of ITI. To estimate the expected length of the pay-
back period, the average costs of ITI were compared with the costs 
of an expected alternative treatment strategy without ITI, that is a 
treatment with prophylactics or on- demand therapy with bypassing 
agents. The payback analysis included all patients who completed 
ITI, except one with ID recurrence, to describe the average costs for 
ITI carried out during early childhood. Nonparametric bootstrapping 
with replacements was applied to define 95% confidence intervals 
for the payback period estimate. Linear mixed model for repeated- 
measures was performed by SPSS software version 21 (IBM Corp., 
Armonk, NY, USA). Hurdle regression analysis with bootstrapping 
was executed by R statistical software version 3.1.1 using func-




The final study sample included 62 PUPs with severe haemophilia A. 
We excluded 7 patients: 4 immigrants were PTPs, previously treated 
with an unknown amount of an unidentified factor concentrate and 
blood components for bleeds, and 3 children had less than 75 ex-
posure days. One child with a severe immunodeficiency, a chronic 
granulomatous disease, was included in the study, without record-
ing the costs unrelated to haemophilia care, such as costs related 
to the treatment at the stem cell transplantation unit. The patients 
were not diagnosed with any other severe conditions or bleeding 
disorders.
The median follow- up time for these patients was 12.7 years 
(range 1.2- 19.3), with a cumulative follow- up time of 698 person- 
years. During the follow- up, 13 (21%) children developed a clinically 
significant inhibitor, 10 (16%) a high- titre one. Table 1 shows the 
baseline characteristics of the study population.
3.2 | Treatment
All our patients were on regular prophylaxis. Fifty- one (82%) fulfilled 
the criterion of primary prophylaxis, while 11 children (18%) had sec-
ondary prophylaxis initiated. The median age of starting home treat-
ment was 1.1 years. During the follow- up, the median frequency of 
prophylactic FVIII concentrate infusions was 3 times a week, with a 
median dose of 26 IU/kg (IQR, 22- 32). The median annual FVIII used 
in prophylaxis was 4136 IU/kg (IQR, 3250- 5113). Trough levels of 
FVIII were used to guide prophylactic treatment in 11 patients (18%). 
Table 1 presents treatment characteristics.
3.3 | Validation
When comparing the annual prophylactic FVIII consumption ex-
tracted from the medical records with the patient- specific data ob-
tained from the Finnish Prescription Register (2012), we did not find 
significant differences among the patients included in the valida-
tion sample. The prophylactic FVIII median consumption observed 
was 4136 IU/kg (IQR, 3250- 5113) in the medical record data and 
4722 IU/kg (IQR, 3510- 5777) in the national register data.
3.4 | Long- term clinical outcomes
Tables 3 shows long- term clinical outcomes. During the follow- up, 
25 (40%) of the patients experienced no joint bleeds, while 19 (31%) 
had one or two. Median ABR was 0.19 (IQR, 0.07- 0.46), and AJBR 
was 0.06 (IQR, 0- 0.24). Inhibitor development was a significant risk 
factor for a higher overall bleed rate, but not for a higher joint bleed 
TABLE  2 Unit costs
Recourse use Price in €* Source
FVIII product 
(per IU)
0.69 Market share weighted price 
per IU (excluding VAT)
rFVIIa (per μg) 0.64 Market share weighted price 
per IU (excluding VAT)
pd- aPCC (per 
IU)
0.85 Market share weighted price 




ICU day 3803 (12)





CVAD insertion 963 Kuopio University Hospital 
tariff
CVAD removal 813 Kuopio University Hospital 
tariff
rFVIIa, recombinant activated factor VII; pd- aPCC, plasma- derived acti-
vated prothrombin complex concentrate; ICU, intensive care unit; nICU, 
neonatal intensive care unit; CVAD, central venous access device.
* Prices at real values in 2014.
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rate; ABR was 0.16 in noninhibitor patients; whereas in inhibitor pa-
tients it was 0.49 (P < .001). AJBR was 0.06 in noninhibitor patients, 
and in inhibitor patients it was 0.15 (P = .26).
In contrast, ABR and AJBR were 3- to 4- fold lower among pri-
mary prophylaxis patients (0.17 and 0. 06) compared with patients 
who received secondary prophylaxis (0.52 and 0.26) (P = .04, and 
P = .001, respectively). Four noninhibitor patients (6%) had a trau-
matic intracranial bleed early in their childhood. No deaths occurred 
during the follow- up. Hospital in- patient days were rarely necessary 
(2.5 per patient annually), with approximately 2 routine annual out-
patient visits to haemophilia centres.
Ten (16%) patients developed a target joint; 4 (6%) children de-
veloped chronic arthropathy, 2 of them requiring synovectomy. The 
incidence of a target joint or an arthropathy at the end of follow- up 
was 18% and 8% in noninhibitor patients and 8% and 0% in inhibitor 
patients (NS). Between children with primary or secondary prophy-
laxis, the incidence of a target joint or an arthropathy did not differ.
During these 698 patient- years of follow- up, our 62 subjects suf-
fered 23 CVAD- related infections. They had 18 CVAD- associated 
bloodstream infections and 5 local tunnel infections. That means 
they had 3.3 CVAD- related infections per 100 person- years.
Of the 13 inhibitor patients, 12 (92%) initiated ITI; in one case 
with a titre drop of 45% to 15 BU/mL 4 months from ID, ITI was post-
poned. Eleven patients (92%) completed ITI after a median duration 
of 8.7 months (range 4.1- 30.1), all achieving tolerance with complete 
or partial success. One HR remained in ITI after an 18- month ther-
apy, with the inhibitor declining to 1.9 BU/mL). A recurrence with a 
peak inhibitor titre 24 BU/mL occurred in one patient a decade after 
ITI, at the age of 14; 17 months of re- ITI led to complete success.
3.5 | Long- term economic outcomes
During the 698 patients- years of follow- up, the mean (SD) annual 
treatment costs were 97 005€ (65 465), per patient and 4391€ 
(3852) per weight kg. These mean annual weight- adjusted costs 
were 2.8- fold (95% CI 1.9- 4.1) higher in the case of inhibitor patients. 
For patients without an inhibitor, they were 3154€ (95% CI, 2887- 
3446); whereas for patients with an inhibitor, they were 8691€ (95% 
CI, 6142- 12 298, P < .01).
Figure 1 shows the mean costs per patient, and Figure 2 shows 
per patient and body weight adjustment, according to the treatment 
entity and age group. Prophylactic FVIII treatment accounted for the 
main cost, except in ages 1- 3, where ITI accounted for more than half 
of the total costs. The mean annual costs for FVIII prophylaxis in-
creased with age until 7, reaching 3172€ per kg (95% CI 2915- 3455). 
Thereafter, they gradually decreased to 2246€ per kg (95% CI 1717- 
2857) at the age of 18. Mean annual total costs between prophylactic 
regimens were about the same: 4437€ per kg (95% CI 3431- 5738) for 
patients with primary prophylaxis and 4183€ per kg (95% CI 3170- 
5519, P = .76) for those with secondary prophylaxis. The proportion 
of costs related to hospitalizations and outpatient visits were 51% 
for age 0 and 11% for age 1. However, since age 2, clotting factor 
consumption dominated costs, accounting for over 94% of the total 




patients, n = 49
Patients with an 
inhibitor history, 
n = 13 P
ABR, median (IQR) 0.19 (0.07- 0.46) 0.16 (0.03- 0.33) 0.49 (0.22- 0.83) <.001
AJBR, median 
(IQR)
0.06 (0- 0.24) 0.06 (0- 0.21) 0.15 (0- 0.26) .26
Patients with 0 
joint bleed, n (%)
25 (40) 21 (43) 4 (31) .32
Patients with 1 
joint bleed, n (%)
15 (24) 12 (25) 3 (23)
Patients with 2 
joint bleeds, n (%)
4 (7) 3 (6) 1 (8)
Patients with ≥3 
joint bleeds, n (%)
18 (29) 13 (26) 5 (38)
Patients with a 
target joint, n (%)
10 (16) 9 (18) 1 (8) .68
Patients with 
arthropathy, n (%)
4 (6) 4 (8) 0 (0) .26
Hospital in- patient 
days, per year, 
median (IQR)
2.5 (1.4- 4.2) 2.4 (1.3- 4) 3.9 (1.9- 7.5) .09
Visits in outpatient 
clinic, per year, 
median (IQR)
2.2 (2.0- 3.0) 2.0 (1.9- 3) 2.7 (2.4- 3.9) <.01
PUPs, previously untreated patients; ABR, annual bleeding rate; AJBR, annual joint bleeding rate; 
IQR, interquartile range.
TABLE  3 Long- term outcomes of PUPs 
with severe haemophilia A
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trend towards lower annual prophylactic FVIII consumption (median 
3645, IQR 2889- 4588) compared to the group with untested trough 
levels (n = 51) (median 4330, IQR 3391- 5200, (P = .12).
The mean (SD) cost of ITI was 383 448€ (259 085). In the patient 
who had an inhibitor recurrence at age 14, the costs of ITI exceeded 
3 483 120€. For this boy, the first ITI cost at age 3 was 352 590€. We 
calculated the mean total costs per person- month and per weight 
for inhibitor patients based on the time period: before or after in-
hibitor development, and before or after ITI. After inhibitor detec-
tion, mean (SD) monthly costs in €/kg quintupled from 259 (229) 
up to 1473 (1984); during ITI, they further doubled to 3097 (2039). 
After ITI completion, the mean monthly €/kg costs decreased to 316 
(97), nearly as low as in noninhibitor patients (mean, 275, SD, 76). 
The expected payback period on ITI completion was 1.81 (95% CI 
0.62- 12.12) years, which indicates a relative short payback period in 
terms of annual cost savings.
4  | DISCUSSION
Our study demonstrated that regular high- dose prophylactic treat-
ment of PUPs with severe haemophilia A leads to excellent long- term 
F IGURE  1 Mean total costs by age group according to a treatment entity. Bleeds: *Including costs for visits in outpatient clinic, 
hospitalizations and coagulation factors during the bleeding episode. Operations: ~Including costs for surgery, hospitalizations and 
coagulation factors. Other: #Including costs for regular hospital visits in outpatient clinic, hospitalizations for central venous access device 
(CVAD)- related infections and prophylaxis with rFVIIa in 2 patients
F IGURE  2 Mean total costs per weight 
by age group according to a treatment 
entity. Bleeds: *Including costs for visits 
in outpatient clinic, hospitalizations and 
coagulation factors during the bleeding 
episode. Operations: ~Including costs for 
surgery, hospitalizations and coagulation 
factors. Other: #Including costs for 
regular hospital visits in outpatient clinic, 
hospitalizations for central venous access 
device (CVAD)- related infections and 
prophylaxis with rFVIIa in 2 patients
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clinical outcomes: both ABR and AJBR were very low. In patients 
with inhibitor development, early childhood ITI therapy was suc-
cessful in terms of joint bleed rates; no difference existed between 
noninhibitor patients and patients with inhibitors. Early childhood 
ITI, regardless of its high initial costs, seems as a cost- neutral option 
in the long run, in fact already in <2 years, that is when comparing a 
hypothetical treatment strategy with the use of prophylactic or on- 
demand therapy with bypassing agents.
To the best of our knowledge, this study is the first of its kind 
using real- world data to examine the long- term clinical and economic 
outcomes of regular prophylactic treatment of PUPs with severe 
haemophilia A. We included inhibitor patients and provide data on 
costs per body weight, representing nearly 700 patient- years of fol-
low- up. All our patients were on early regular prophylaxis started 
at the median age of 11.8 months. The median (IQR) annual FVIII 
consumption in prophylaxis was 4136 IU/kg (3250- 5113). During the 
long follow- up (median 12.7 years), 40% of our patients experienced 
no joint bleed; over two-thirds (71%) experienced fewer than 3 joint 
bleeds. At the end of the follow- up, only 4 children had a target joint, 
which developed into chronic arthropathy. Thirteen (21%) patients 
developed a clinically significant inhibitor.
The mean (SD) overall total annual treatment costs per patient 
were 4391€/kg (3852). All patients who completed ITI achieved tol-
erance with complete (36%) or partial (64%) success. The mean (SD) 
total costs for ITI were 383 448€ (259 085), and at ages 1- 3, ITI ac-
counted for more than half of the total costs; whereas at age above 
3, prophylactic FVIII treatment dominated.
A few long- term outcome studies of adult noninhibitor patients 
with regular prophylaxis have reported both clotting factor costs 
for prophylaxis and other healthcare costs such as surgery, hospi-
talizations and healthcare visits 5005; 455.6 Most paediatric stud-
ies report only the costs of prophylaxis 4602; 459,1 and resource 
utilization and related costs are only estimated with hypothetical 
patients 456,22 without real- world data, which were the source of 
our approach. Although our study is retrospective, its advantages 
include long follow- up time, the uniform guidelines in Finnish paedi-
atric haemophilia care, and the inclusion of national data of all con-
secutive PUPs during the 19- year study period, and all treatment 
costs covering the neonatal period to adolescence. Finland has cen-
tralized patient care to university hospitals, and our national hae-
mophilia expert team of paediatric haematologists has unanimously 
agreed upon recommendations for treatment, prophylaxis and ITI. 
In addition, our study analyses real- world data with a top- down 
costing approach, reporting patient and body weight- adjusted costs. 
Simultaneous patient- specific data from the Finnish Prescription 
Register validated the FVIII consumption data extracted from 
medical records, showing that the amount of FVIII dispensed from 
pharmacy did not deviate from the prescribed doses. This finding 
ensures that our patients and their parents were very adherent to 
prophylaxis.
The limitations were the retrospective nature of our study, and 
a relative small sample size. Under- reporting of bleeding frequency 
is possible, especially in the case of soft tissue or minor bleeds; in 
addition, the diagnosis of a bleeding event is generally subjective. 
However, both parents and patients were instructed to report and 
confirm all joint and other significant bleeds to the hospital; the 
treatment was guided to be initiated at the hospital and continued 
at home with a close contact. This clinical practice may diminish the 
possible impact of under- reporting. It has been shown that the expe-
rience of symptoms, positive belief in treatment necessity and good 
relation with the healthcare provider are motivators for high adher-
ence 503.23 Thus, by educating and supporting parents and patients, 
we can improve the adherence for haemophilia treatment and prob-
ably also for recording bleeds. All bleeding events were recorded to 
patients’ medical records by a specialist in haemophilia care. At the 
time of data collection, all data were registered by the same paedi-
atric haematologist, KV, not by local personal, to ascertain coherent 
data collection across the centres.
The standard deviation of the mean annual treatment costs was 
wide, representing the variability in treatment intensity and costs 
between noninhibitor patients vs patients with high- titre inhibitors 
using high- dose ITI therapy in combination with bypassing clotting 
agents. The wide distribution of cost data between different studies 
and even in- between patients in the same study has been found in 
several previous studies among noninhibitor patients5; 4729; 455,6 
but especially among inhibitor patients 4697; 4729; 457.24 Despite 
the wide deviation, mean total costs kg−1 remained stable during the 
childhood except in ages 1- 3, and 14, when the increment of costs 
was due to ITI (Figure 2). Higher variation between mean costs per 
patient and cost increase by age indicates the effect of increasing 
weight (Figure 1).
At the end of follow- up, patients were relative young (median 
age, 12.7 years). However, early childhood, in particularly, is the crit-
ical treatment period, affecting long- term joint health and quality 
of life in adulthood. The best long- term joint outcome is achieved 
starting primary prophylaxis at the earliest age25-27 even before 
the first joint bleed compared with the strategy starting second-
ary prophylaxis after one or more joint bleeds. The number of joint 
bleeds before starting prophylaxis has a stronger association with 
the outcome than the age upon starting prophylaxis.28 In all, with 
our results of scarce joint bleeds during childhood, we assume good 
long- term joint health reaching also to adulthood.
The prophylactic FVIII dosing regimen in Finland corresponds to 
the high- dose Swedish one 45829; 49930; 462.31 Although prophy-
laxis in Finland is implemented mainly via central venous devices, 
the need for hospitalization was uncommon; costs related to hos-
pitalizations and outpatient visits constituted less than 6% of the 
total costs beyond 1 year of age. The quality of life was beneficial: 
regarding joint health and practical prophylaxis via ports at home. 
In addition, the patient age at home treatment start was low (me-
dian, 1.1 years) compared with other western countries; this was 
3.3 years in Sweden 4556 and 4.0 in Denmark 467.32 As we have re-
ported earlier, long- term CVAD- related complications did not occur, 
and the incidence of inhibitor development was relatively low (21%) 
46510; 452.11 Despite inhibitor development, joint health in inhibi-
tor patients remained good. ITI results were excellent; all patients 
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(n = 11) who completed ITI achieved tolerance with either complete 
or partial success.
Although the clinical outcomes are favourable, the high total 
costs of therapy demand our continued evaluation on how to reduce 
prophylactic FVIII doses, at least in certain patients. In one- fifth of 
the cohort, trough levels of FVIII were useful in guiding appropriate 
prophylactic treatment towards 16% lower annual FVIII consump-
tion. Lower FVIII consumption did not predispose to target joints or 
arthropathy. We suggest that individualized therapy protects from 
bleeding complications with cost reductions, but further analyses 
are warranted.
The development of FVIII- neutralizing antibodies remains the most 
severe and costly complication of haemophilia therapy. Our results 
with real- world data are in line with the findings from a recent health 
economic modelling study, which reported that the lifetime costs of 
treating adult patients with inhibitors are lower for ITI compared to 
on- demand or prophylaxis with bypassing agents 457.24 In our study, 
after inhibitor detection, direct monthly total costs €/kg quintupled 
from 259€ to 1473€ mainly due to the use of bypassing agents, corre-
sponding to an annual total cost of 1.3 million € for an average weight 
(75 kg) adult. During ITI, costs further doubled to 3097€, but after 
successful ITI, the FVIII consumption of prophylaxis and total costs 
decreased to the level of noninhibitor patients. The expected payback 
period estimate of <2 years indicated that, ITI appears cost- neutral 
(ie, compared to on- demand or prophylaxis with bypassing agents) 
after a relatively short period: the savings of successful ITI, fully offset 
the incremental costs due to FVIII used for ITI during the 1.81 years. 
However, this estimate based on the small number of patients with ITI 
and should be interpreted with caution. The mean (SD) cost for ITI was 
383 448€ (259 085) during early childhood, but it increased ten- fold 
by age 14 (3 483 120€). Without prospective randomized trial con-
firming that treatment delay confers benefit, the current practice has 
been to delay the start of ITI until the inhibitor titre is <10 BU/mL 
with anticipated enhanced success. In a retrospective study in 2 U.S. 
haemophilia treatment centres, a titre >10 BU/mL at ITI start did not 
impact the outcome in subjects with ITI initiation within 1 month of 
detection 470.33 Also, health economic consequences emphasize the 
importance of prompt ITI regardless of the inhibitor titre.
As the use of new extended half- life (EHL) factor concentrates 
is increasing, our study with reliable data about real- world practices 
is crucial for the future, to critically compare long- term costs (and 
potential benefit) between the current and the future treatment 
options. The data provide relevant information to support decision- 
making related to new and usually even more expensive treatments, 
including EHL products, the bispecific antibody recognizing FIX and 
FX, and gene therapy.
Our earlier results have emphasized the role of early primary 
prophylaxis via ports to prevent major bleeds and decrease inhibitor 
incidence 452.11 Our current study demonstrates that early high- 
dose prophylaxis provides excellent long- term clinical outcomes. 
Moreover, rapid ITI therapy during early childhood is successful 
and seems cost- neutral due to its relatively short expected payback 
period.
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